GNS
NEUTRALGenus Appoints New Financial Adviser and Joint Corporate Broker
The animal genetics company has appointed J.P. Morgan Securities plc as its new Financial Adviser and joint Corporate Broker.
Genus
2,025.00GBX
-2.41%
Market Cap
1.35B
Volume
16.7k
9% of avg
P/E Ratio
0.24
EPS (TTM)
86.13
Beta
0.58
Day Range
2,025.00p - 2,075.00p
52 Week Range
1,424.00p2,025.00p2,160.00p
2,025.00p
Upcoming Events
31 May 2025
Professor Jason Chin to step down from Genus Board
GNS
NEUTRALGenus Receives FDA Approval for PRRS Resistant Pig
The animal genetics company has received regulatory approval for its innovative PRRS Resistant Pig product in the US market.
GNS
NEUTRALGenus plc Notifies Major Shareholding Change
The healthcare company has received notification of a change in major shareholdings.
GNS
NEUTRALGenus plc Notifies Major Shareholding Change
The healthcare company has received notification of a change in major shareholdings.
GNS
NEUTRALGenus Announces Director Share Dealings
The healthcare company has announced details of restricted stock awards granted to an executive, including vesting and sale of shares to cover tax liabilities.
GNS
NEUTRALGenus PLC Announces Change in Major Shareholder
The healthcare company has announced that BlackRock, Inc. has increased its stake in the firm to over 5% of the voting rights.
GNS
NEUTRALGenus Appoints New Chief Financial Officer
The healthcare company has appointed a new Chief Financial Officer to succeed the retiring incumbent.
GNS
NEUTRALGenus CEO Exercises Options, Retains Shares
The CEO of this major biotechnology company has exercised stock options and sold a portion of the resulting shares.
GNS
GOODGenus PLC Reports Strong Half-Year Performance with 19% Profit Growth
The animal genetics company reported a 19% increase in adjusted operating profit, strong cash generation, and strategic progress in key markets. Despite currency headwinds, the outlook remains positive with increased profit expectations for FY25.
GNS
NEUTRALGenus Announces Non-Executive Director Retirement
The animal genetics company announces the retirement of a Non-Executive Director, who is leaving to take on a new role.